Investors looking for a disciplined, long-term method for choosing stocks frequently consider the principles of legendary fund manager Peter Lynch. His strategy, outlined in his book One Up on Wall Street, centers on finding companies with lasting growth, sound financial condition, and fair valuations, a philosophy often called Growth at a Reasonable Price (GARP). The central concept is to locate businesses that are expanding consistently, but whose share prices do not yet show their complete possibility, letting investors purchase before the wider market recognizes this.
A recent filter using Lynch's important measures has identified United Therapeutics Corp. (NASDAQ:UTHR) as a possible candidate. The biotechnology firm, which creates and sells treatments for pulmonary arterial hypertension and other severe illnesses, seems to match multiple central parts of the Lynch investment approach.
Match with Peter Lynch's Central Measures
The Lynch filter uses defined, measurable rules to search for companies that mix growth with carefulness. United Therapeutics fits a number of these important standards:
- Lasting Earnings Growth: Lynch preferred companies with steady, but not extreme, earnings growth. He usually sought a five-year earnings-per-share (EPS) growth rate between 15% and 30%, thinking growth outside this band was frequently not lasting. United Therapeutics states a five-year EPS growth rate of 19.23%, putting it firmly inside Lynch's desired range. This shows a record of stable, controlled increase.
- Fair Valuation using the PEG Ratio: Maybe the most important Lynch measure is the Price/Earnings to Growth (PEG) ratio, which tries to price a stock in relation to its earnings growth. A PEG ratio of 1 or less implies the stock may be fairly priced for its growth path. United Therapeutics has a PEG ratio of 0.97, indicating that its present price is not excessive when its historical growth is considered.
- Outstanding Financial Condition: Lynch required companies with solid balance sheets to endure economic declines. Two key rules point out UTHR's sound financial standing:
- Debt/Equity Ratio: The company has a Debt/Equity ratio of 0.0, meaning it functions with no debt. Lynch firmly favored low debt, often looking for a ratio under 0.25, making UTHR's balance sheet outstanding.
- Current Ratio: A gauge of short-term cash availability, a Current Ratio above 1 shows a company can comfortably meet its immediate responsibilities. UTHR's ratio of 6.60 shows very good financial adaptability and security.
- High Profitability (ROE): Return on Equity (ROE) calculates how well a company creates profits from shareholder equity. Lynch wanted an ROE above 15%. United Therapeutics provides an ROE of 18.81%, verifying it is a very profitable firm that uses its money productively.
Basic Condition and Valuation Summary
A wider view of the company's basic profile supports the image shown by the Lynch filter. According to a detailed basic examination, United Therapeutics gets a 7 out of 10 total, with high marks in profitability and financial condition.
- Profitability Quality: The company receives a nearly perfect score of 9/10 for profitability. It keeps sector-leading margins, including a Profit Margin of 41.94% and an Operating Margin of 47.63%, which place in the highest group of its biotechnology competitors. Its returns on assets, equity, and invested capital are all very good.
- Very Strong Balance Sheet: The health score is also a high 9/10. The lack of debt and a very high Altman-Z score (20.90) almost remove failure risk. The high Current and Quick Ratios give plenty of available cash.
- Valuation Setting: The valuation score is a moderate 6/10. While its Price/Earnings ratio of 18.74 seems high alone, it is actually lower priced than over 93% of its industry competitors and sits under the present S&P 500 average. This contrast points out the high prices normal in the biotech field and implies UTHR may be a relative bargain inside its category.
A Candidate for the Long-Term Investor
For an investor using Peter Lynch's principles, United Therapeutics offers a strong case. It is a profitable company in a focused, clear field, treating chronic life-threatening illnesses, that has increased earnings at a lasting double-digit rate. Importantly, this growth is combined with a clean, debt-free balance sheet, giving a major safety buffer. The PEG ratio implies the market has not overvalued this mix of growth and quality.
While previous results are not a promise, the company's financial traits match the kind of business Lynch suggested keeping for the long term. It shows the "growth at a reasonable price" thinking, where the attention is on lasting business results instead of short-term market guessing.
Interested in reviewing other companies that match the Peter Lynch investment model? You can use the filter yourself and see the most recent outcomes here.
Disclaimer: This article is for information only and does not form financial guidance, a suggestion, or an offer to purchase or sell any securities. The Peter Lynch strategy is one of many investment methods, and past filter outcomes are not a sign of future results. Investors should do their own complete study and think about their personal money situation and risk comfort before making any investment choices.